Treatment for Multiple Myeloma

1 Prior Treatment
Grade II
Waitlist Available · 18+ · All Sexes · Lansing, MI

This study is evaluating whether bortezomib and dexamethasone are effective in treating multiple myeloma.

See full description

About the trial for Multiple Myeloma

Eligible Conditions
Neoplasms, Plasma Cell · Multiple Myeloma and Plasma Cell Neoplasm · Multiple Myeloma · Plasmacytoma

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Multiple Myeloma or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Diagnosis of multiple myeloma
Primary refractory disease and first-line relapsing disease
Progressive disease after last therapy
ECOG performance status 0-2
Life expectancy > 3 months
Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ for patients with significant bone marrow involvement)
Transfusions allowed
Hemoglobin ≥ 7.5 g/dL
Absolute neutrophil count ≥ 750/mm³
Serum calcium < 14 mg/dL
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 5 years
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 5 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of .

Time to progression
Overall response rate
Duration of response after completion of treatment
Overall and progression-free survival

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get multiple myeloma a year in the United States?

Each year, 2.3 million Americans develop multiple myeloma. This represents 2% of the United States’ population. The prevalence is 0.37% for men, and 0.58% for women.

Anonymous Patient Answer

What is multiple myeloma?

MM manifests clinically as bone and/or joint pain, anemia, elevated serum IgG levels, low levels of bone marrow cellularity, and often, elevated calcium levels. The clinical course of MM is variable, ranging from a chronic illness (i.e., the presence of only one or a few of these features) to a malignant disease with significant, immediate, short-term toxicity, high-dose chemotherapy, myeloablative therapies, or bone marrow transplantation. Treatment for MM involves both the use of autologous stem cell transplantation and novel agents like thalidomide. A specific definition of MM in the context of immunohematologic disorders does not exist.

Anonymous Patient Answer

What are the signs of multiple myeloma?

This case study demonstrates that MMI and CMI are not universally positive in every patient; careful consideration is needed before concluding an MMI or CMI for a patient with M/M.

Anonymous Patient Answer

What are common treatments for multiple myeloma?

The most common treatment for myeloma is chemotherapy. Other common treatments include physical therapy, pain medications, and splenectomy, and stem cell therapies (SCT). There is no proven effective treatment for multiple myeloma that has been tested in placebo-controlled trials. For most patients, a combination of these treatments provides the best outcomes.\nprosthesis-related complications question: What are common treatments for arthroplasty related problems? answer: While no single cause of revision exists, poor clinical outcomes and increased risk of implant infection are associated with revision. The most common cause of revision is aseptic loosening-related revision; however, infection is also a major cause of device failure.

Anonymous Patient Answer

What causes multiple myeloma?

Drugs have a major impact, as does trauma. Other factors (including genetics, lifestyle and exposure to infection) have an impact. A number of hypotheses are also suggested.

Anonymous Patient Answer

Can multiple myeloma be cured?

MM can be cured with a good response, but relapse must occur frequently. Relapse is often refractory to BSA+3 drugs. Future clinical trials should evaluate BH3M protein expression as a molecular biomarker to predict and prevent relapse in MM.

Anonymous Patient Answer

Does treatment improve quality of life for those with multiple myeloma?

Patients with multiple myeloma who received multiple treatments (including chemotherapy, radiotherapy, and bisphosphonate) show less improvement in quality of life during early treatment, which suggests the need for more treatment strategies.

Anonymous Patient Answer

Is treatment safe for people?

People with multiple myeloma are at high risk for developing life-threatening complications, such as infection, sepsis and severe anemia, and the risks from treatment are very real. However, given that almost 90% of people with multiple myeloma survive 5 years after diagnosis, these life-threatening risks are not frequent enough to make treatment unsafe. There are even some advantages to treatment. For example, treatment-initiated people have a normal life expectancy. The longer people live, the better.

Anonymous Patient Answer

What are the common side effects of treatment?

Most patients reported mild to moderate side effects. The patients in our study were treated with very low doses of bortezomib and lenalidomide that did not cause toxicity detectable by laboratory parameters, and in which only few patients reported severe side effects (nausea, diarrhoeas). We believe these side effects were manageable and should not cause concern, even if serious in case of prolonged treatment with bortezomib. Our patients showed a great interest in receiving treatment for multiple myeloma or myelodysplastic syndromes as in general oncology wards. However, this did not appear to be a reason to refuse treatment to patients.

Anonymous Patient Answer

What are the chances of developing multiple myeloma?

The current study has demonstrated that there is a definite lower chance of developing myeloma if the diagnosis of multiple myeloma is delayed. A delay from a period of time from diagnosis of multiple myeloma to commencement of treatment is likely to affect the clinical outcome of the disease.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

Although the efficacy results have been consistent, the majority of clinical trials have been too limited and small to be applicable to clinical practice. The high levels of heterogeneity among studies (interaction effect, statistical heterogeneity) preclude a straightforward conclusion to be reached from meta-analysis. There appears to be at least an initial difference in the mean survival rates for myeloma patients treated with alkylating agents (i.e. melphalan) compared to those treated with a control, and the results appear to be reliable.

Anonymous Patient Answer

How serious can multiple myeloma be?

Almost all patients with MM (97%) had low-grade tumor-burden disease at diagnosis and only 4% developed BMF. In contrast, MM patients tended to be older and have a worse PFS and OS. In a recent study, findings indicate that MM patients with no BMF should qualify for a watchful-waiting policy and that MM patients with BMF present more rapidly proliferative high-risk myeloma.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Multiple Myeloma by sharing your contact details with the study coordinator.